Alkermes, Inc.
Clinical trials sponsored by Alkermes, Inc., explained in plain language.
-
New drug combo aims to curb weight gain in teens on mental health meds
Disease control Recruiting nowThis study is testing if a new combination medication (OLZ/SAM) causes less weight gain than the standard drug olanzapine in children and teenagers with schizophrenia or bipolar I disorder. About 220 participants, aged 10-17, will take either the new combination or standard olanz…
Phase: PHASE3 • Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated Apr 02, 2026 04:12 UTC
-
Extended trial tests new sleep disorder medication
Disease control Recruiting nowThis study continues testing ALKS 2680 tablets for people with narcolepsy or idiopathic hypersomnia who completed earlier trials. Researchers want to see how safe the medication is over a longer period and whether its benefits last. Participants will take the tablets regularly to…
Phase: PHASE2, PHASE3 • Sponsor: Alkermes, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New pill aims to wake up people with extreme sleepiness disorder
Symptom relief Recruiting nowThis study is testing whether a new tablet called ALKS 2680 can safely reduce excessive daytime sleepiness in people with idiopathic hypersomnia, a disorder that causes severe sleepiness despite adequate sleep. About 96 participants will take either the medication or a placebo (i…
Phase: PHASE2 • Sponsor: Alkermes, Inc. • Aim: Symptom relief
Last updated Mar 23, 2026 15:18 UTC